New quantitative data suggests that 30% of the surgeries performed for non-small cell lung cancer patients in a community-wide clinical study were deemed unnecessary.
A new drug, ceritinib, appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system.
Eliminating the protein Mcl-1 could make radiation and chemotherapies more effective in treating the most common and deadly of all cancers, non-small cell lung cancer.
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|